Vir Biotechnology
Vir Biotechnology’s Phase 2 Data for Hepatitis D Combo Regimen Highlights Market Potential
Vir Biotechnology; Phase 2; hepatitis D; combination therapy; tobevibart; elebsiran; SOLSTICE trial; undetectable HDV RNA; market potential; ECLIPSE program
Vir Biotechnology Acquires T-Cell Engagers from Sanofi, Reduces Staff by 25% in Strategic Pipeline Shift
Vir Biotechnology, Sanofi, T-cell engagers, pipeline switch-up, staff reduction, biotech industry, pharmaceuticals
Vir Biotechnology Lays Off 25% of Staff, Shifts Focus to Cancer Research in Sanofi Partnership
Vir Biotechnology, layoffs, Sanofi partnership, cancer research, monoclonal antibodies
Vir Biotechnology Reports Positive Update on Hepatitis Delta Combination and Monotherapy Treatments
Vir Biotechnology, Hepatitis Delta, Combination Therapy, Monotherapy, Clinical Trial, EASL Congress